Eye News August / September 2017 Press Releases Updated

Press Release section for all the latest new products, product developments and news from companies within the field.

THE BIMONTHLY REVIEW OF OPHTHALMOLOGY AUGUST / SEPTEMBER 2017 • VOL 24 NO 2 www.eyenews.uk.com

@EyeNewsMag

ISSN: 1368-8952

NEWS AND PRODUCT UPDATE

Haag-Streit UK offers an enhanced LED illumination system for older slit-lamps

Carleton Optical appointed exclusive distributors for Phoenix Clinical

Haag-Streit UK (HS-UK) is offering the opportunity to enhance older HaagStreit slit-lamps, by converting them to utilise a 14mm LED illumination system.

Tungsten illumination can be problematic when the bulb needs to be replaced as it can lead to equipment down-time and the frequency of bulb replacements in demanding clinics can be costly. LED illumination is energy-efficient, reduces the necessity to replace bulbs and has the added benefit of providing improved illumination of the anterior segment for clinical diagnosis.

LED conversion can be performed on older BQ 900, BP 900, BM 900 and BX 900 Haag-Streit slit-lamps. An LED enhancement is quick and simple to implement. The process can be performed by a trained HS-UK Service Engineer, at the customer’s premises, in just a few short hours.

Carleton Optical is delighted to announce been appointed exclusive distributor in the UK for Phoenix Clinical, manufacturers of the new ICON Paediatric Retinal Camera.

The new camera generated huge interest when it was exhibited for the first time at the recent Royal College of Ophthalmologists Congress in Liverpool.

ICON is a handheld wide field of view retinal camera, optimised for paediatric patients to age 18. The design also targets high contrast imaging including patients with darkly pigmented retinas, providing very high resolution, even at a wide field of view, eliminating the need for multiple high-cost objective lenses.

ICON is connected to the cart by a simple control / USB cable. No bulky, heavy or fragile fibre optic cables. The cart is lightweight with motorised height adjustment and easily moveable.

For further information contact: Haag-Streit UK Tel: +44 (0)1279 883829 E: ledupgrade@haag-streit-uk.com http://hsuk.co/ledconversion

For further information contact: Carleton Optical Equipment Ltd. T: +44 (0)1494 775811 E: carleton@carletonltd.com www.carletonltd.com

EMS Healthcare launches flexible new mobile ophthalmology unit

EMS Healthcare, the UK’s leading provider of mobile ophthalmology units, has launched its latest macular unit, Quest+, designed to help alleviate the growing pressures and demands facing NHS Trusts in association with macular disease.

The new 40-foot unit has all the required facilities of a macular clinic, including a welcoming patient reception/waiting area, a visual acuity room, a consultation and OCT scanning room, and a HTM-compliant clean room. It is fully DDA-compliant and incorporates medical grade materials that meet infection control standards, meaning patient care is never compromised. These facilities enable an independent one-stop follow up assessment and treatment service, eliminating the need for patients to re-enter the main hospital environment.

Taking just one hour to set up, Quest+

can be relocated on a daily basis, aiding clinicians in the delivery of out of hospital and community-led care, a national target underlined throughout the NHS’s Five Year Forward View. This presents particular benefits to patients with impaired vision, for whom the option to attend appointments closer to home offers a more convenient experience than travelling to and from hospitals for regular intravitreal injections.

The official launch of Quest+ took place at May’s Royal College of Ophthalmologists (RCO) Annual Congress, where it made its debut showcase to leading industry professionals. Feedback given by ophthalmologists during the week proved the unit offers suitable flexibility to assist NHS Trusts when dealing with insufficient clinic space, vital hospital refurbishment works or when looking to deliver care in the

community.

EMS Healthcare’s listing on the NHS’s Mobile Diagnostics, Theatres, Treatment and Therapy Services framework enables healthcare providers to access its mobile medical units through a much quicker procurement process, meaning trailers can be deployed and installed within six to eight weeks of initial enquiry.

For further information contact: EMS Healthcare Ltd T: +44 (0)151 350 1500 E: info@ems-healthcare.com www.ems-healthcare.com

eye news | AUGUST/SEPTEMBER 2017 | VOL 24 NO 2 | www.eyenews.uk.com

83

NEWS AND PRODUCT UPDATE

Haag-Streit UK announces further ‘Improving Outcomes’ biometry courses to be held in Leeds Haag-Streit UK (HS-UK) has confirmed two further ‘Improving Outcomes’ biometry courses, which will be held at the Radisson Blu Hotel, Leeds on 19 and 20 October 2017.

HS-UK has finalised an exciting programme for these two additional courses, which includes lectures on topics such as; ‘TORIC IOL surgery’ and ‘IOL power calculation’. Each day will also include practical, hands-on workshops with state-of-the-art biometry equipment.

Speakers for the event are confirmed as; Mr David Sculfor, Consultant Optometrist at Stoke Mandeville Hospital and Mr Peter Wilson, Consultant Ophthalmologist at NHS Fife & Forth Valley. Both are widely-recognised as experts in their field.

The price for each course is just £100 and delegates will be able to claim 6.5 CPD points for their attendance on the day.

For further information contact: Haag-Streit UK Tel: +44 (0)1279 883829 E: ceat@haag-streit-uk.com www.haagstreituk.com/improvingoutcomes

Precision quality every time – use our Sterile Single-use Birks Tying Forceps Achieve consistent results with our Sterile Singleuse Birks Tying Forceps.

The well-balanced ergonomic design and knurled handle, provide an effective grip during delicate procedures. With 0.3mm tips and 5mm platforms, our forceps deliver the precision and accuracy you need.

Our high-quality stainless steel Birks Tying Forceps are an effective replacement to reusable devices and offer the best solution when repeated

sterilisation can damage fine instruments.

To arrange your free sample of our Birks Tying Forceps please contact us.

For further information contact: DTR Medical Ltd T: +44 (0)1792 797910 E: marketing@dtrmedical.com www.dtrmedical.com

SP.eye® the world’s only sharps safe intravitreal injection system SP.eye® is a one-piece device combining a 30G needle, delivery guide and fully integrated, sharps safe system, for intravitreal injections.

A first of its kind, SP.eye® is the only intravitreal injection device designed to be safer for the patient and the injector.

SP.eye® allows any suitably qualified medical professional to deliver intravitreal therapies, including all current anti-VEGF agents (prefilled or vial filled syringes).

The SP.eye®’s guiding footplate ensures a precise and stable delivery of the intravitreal injection.

SP.eye® requires no assembly, and reduces the steps in the intravitreal workflow. After use, it is easily locked safe before being disposed of.

The device complies with British and European law, use of sharps safe devices, and the Royal College of Nursing’s guidance on the use of sharps.

Buy from NHS Wales Procurement “Oracle” or direct from SD Healthcare.

For further information contact: SD Healthcare T: +44 (0)161 776 7626 E: info@sdhealthcare.com www.sdhealthcare.com

Visiometrics HD Analyzer The HD Analyzer provides critical objective data for better patient outcomes in cataract surgery, dry eye treatment and refractive surgery. It is the only instrument in the eye industry capable of objectively measuring light scatter, delivering an empirical evaluation of patients’ visual quality.

It also offers the only tear film analysis based on visual function.

The HD Analyzer objectively measures light scatter to quantify exactly what and how the patient sees. It allows doctors to see lens opacification at its earliest stage and track small changes in a patient’s lens over time. The HD Analyzer’s reports are an excellent education tool to help patients make an informed decision about

84

treatment options.

In dry eye treatment, the HD Analyzer is able to quantify dynamic changes in visual quality after blinking – even in clinically asymptomatic subjects. Detecting asymptomatic cases ensures the best possible surgical outcomes for these patients.

For further information contact: Benjamin Jung (Sales Manager for Europe) Visionmetrics E: benjamin.jung@visiometrics.com www.Visiometrics.com

eye news | AUGUST/SEPTEMBER 2017 | VOL 24 NO 2 | www.eyenews.uk.com

NEWS AND PRODUCT UPDATE

Spectrum launches the new Membrane FEELceps™ by Oertli Spectrum is pleased to announce the launch of the new Membrane FEELceps™ by Oertli, which will enable you to save money on each procedure.

Direct and perfectly controlled translation of the surgeon’s fingertip actuation to the tip of the forceps is essential for successful peeling. With the FEELceps™, the surgeon can clearly feel both the closing-point and the responsive opening mechanism and with a 360 degree actuation, FEELceps™ appears gentle and fatigue free for the surgeon’s sensitive hand.

The handle offers a clear mark identifying the grasping point, which indicates the position of the jaws ensuring less manipulation.

With an outstanding holding force, the Oertli FEELceps™ portfolio has been developed and manufactured by Oertli in Switzerland.

Oertli FEELceps™ are available in two different sizes, 23G and 25G Symmetrical and Asymmetrical.

Feel the precision, feel the grip, choose FEELceps™.

For further information contact: Spectrum T: +44 (0)1625 618816 E: enquiries@spectrum-uk.co.uk www.spectrum-uk.co.uk

Now on prescription – Clinitas® Hot Eye Compress

Altacor, a specialist ophthalmic company based in Cambridge UK, are pleased to announce the addition of the Clinitas® Hot Eye Compress to its portfolio of dry eye and ocular surface products.

The Clinitas Hot Eye Compress is a new eye mask designed to give effective relief from MGD, blepharitis, dry eye disease and associated symptoms.

Altacor have replaced their existing lephaMask® with this new and improved proposition for healthcare professionals. The new Clinitas Hot Eye Compress has been carefully selected to offer patients optimal features and benefits and has the additional advantage of being available to prescribe.

It is reimbursable on the NHS drug tariff at a low cost of just £7.49.

Product features included a removable washable cover for hygiene, which patients showed a preference for, as well as an adjustable strap for comfort. The mask can be reused at least 365 times and can be heated in the microwave or oven for convenience.

To prescribe the Clinitas Hot Eye Compress, simple write “Clinitas Hot Eye Compress” on your next prescription.

For further information contact: Altacor T: +44 (0)1223 421411 E: info@altacor-pharma.com www.altacor-pharma.com

E-Eye – the long lasting solution for dry eye management using patented IRPL® technology Exclusively available in the UK through Grafton Optical, E-Eye is the first and only medical device in the world using IRPL® that has been specifically designed for the treatment of dry eye due to meibomian gland dysfunction (MGD).

E-Eye uses a unique patented Intense Regulated Pulsed Light (IRPL®) technology to regenerate the function of the meibomian glands and improve the quality of their secretions. This new type of polychromatic pulsed light produces perfectly calibrated and homogenously sequenced light pulses which stimulate the parasympathetic nerves. This in turn encourages the meibomian glands to restore their natural lipid flow, reducing tear evaporation and preventing the eyes from becoming dry.

In most cases, dry eye symptoms will significantly improve after three sessions, carried out over 45 days (Day 0/ Day 15/ Day 45). For 60% of patients results can last up to three years.

• • • • • •

Painless, non-invasive and affordable Fast results – sessions are completed in a matter of minutes Clinical studies with a 90% satisfaction rate on the first two sessions 95.7% of patients recommend the treatment 55% of patients don’t use eye drops anymore 82.6% of patients have symptom improvements.

Brian Bowles, Managing Director of Grafton Optical says “We have seen huge interest and success with the E-Eye since its launch in the UK last year. It offers huge benefits not only to patients suffering from MGD related dry eye but also to practices wishing to increase their income.”

The E-Eye is 100% developed and made in France by ESW Vision, the world’s largest IPL device manufacturer.

For further information contact: Grafton Optical T: +44 (0)1923 233980 E: sales@graftonoptical.com

eye news | AUGUST/SEPTEMBER 2017 | VOL 24 NO 2 | www.eyenews.uk.com

85

NEWS AND PRODUCT UPDATE

Haag-Streit UK announces two new Slit-Lamp Imaging Courses Haag-Streit UK (HS-UK) has confirmed dates for two new Slit-Lamp Imaging Courses. These courses will take place on 15 August at the Radisson Hotel, Bristol and 17 August at the Radisson Edwardian Hotel, Manchester.

The aim of the Slit-Lamp Imaging Courses is to provide attendees with a detailed overview of this highly-skilled ophthalmic imaging discipline.

The day will feature expert advice from slit-lamp imaging specialists on how to get the most from your imaging module and will offer insights into the clinical importance of high-quality slit-lamp images.

Each course will include practical, hands-on

workshops, which will support a range of subjects, including; diffuse, focal & indirect illumination and retinal imaging using retro illumination.

The price for each course is just £100 and delegates will be able to claim 7.5 CPD points for their attendance on the day.

For further information contact: Haag-Streit UK Tel: +44 (0)1279 883829 E: ceat@haag-streit-uk.com www.haagstreituk.com/slitlampimaging

Record numbers attend annual Heidelberg Engineering Academy Masterclass

Infrared fundus image with OCT (top), autofluorescence (bottom left) and OCT Angiography (bottom right) from OCT LIVE Masterclass patient with AMD.

Over 100 eye care professionals attended the 6th Annual Heidelberg Engineering Academy Masterclass, making it the company’s biggest

Masterclass yet. The event, which took place at the historic Royal Liver Building in Liverpool, showcased the latest innovations in non-invasive vascular imaging of the retina.

Dr Pearse Keane from Moorfields Eye Hospital, London, chaired the evening whilst Professor Usha Chakravarthy from Queens University Belfast, and Dr Roberto Gallego-Pinazo from Oftalvist Valencia, Spain, presented the latest research on MultiColor imaging and OCT Angiography. A highlight of the Masterclass was the OCT LIVE segment, where two patients from the Royal Liverpool University Hospital were scanned live on the big screen in front of the audience using the SPECTRALIS Imaging Platform.

The audience and speaker panel were invited to discuss their thoughts on the patient’s diagnosis and a lively debate ensued.

“OCT, MultiColor, autofluorescence and OCT angiography imaging were all performed live in front of the audience and compared to baseline scans,” explains Christopher Mody, Director of Clinical Services. “Doctors called out requests for

additional imaging on the patients, including customised OCT scan placement, which we were able to perform on the spot for them. It was a unique experience and it was clear that the multimodal imaging approach increased the clinician’s certainty in the diagnosis.”

The patient volunteers stated that they found the event fascinating and they both independently made the decision to selflessly donate their honorariums to sight care charities.

The next OCT LIVE event from Heidelberg Engineering will be on the subject of glaucoma and optic neuropathies and will take place on 28 and 29 July at Plymouth University.

For further information contact: Heidelberg Engineering Ltd. T: +44 (0)1442 502 330 E: Info-UK@HeidelbergEngineering.com www.heidelbergengineering.com

Ocu-GLO Human Vision Formula

The New Optopol REVO nx OCT with Angio

Ocu-GLO Human Vision Formula™ is a blend of naturally occurring antioxidants that were specifically chosen to synergistically support the health of the human eye. This formula was designed based on research data from the Age-Related Eye Disease Studies (i.e.

ARED studies I and II). The ARED studies are a major clinical trial sponsored by the National Eye Institute to identify the leading causes of vision loss in older humans.

For contents and further information visit www.visionarysurgicalsolutions.com

The wolrds fastest fully automated OCT at 110, 000 A scans per second and an axial resolution of 5μm in tissue ~2,6μm digital.

Single 3D retina examination is enough to perform both retina and glaucoma analysis based on retinal scans.

Optional angiography SOCT module allows visualisation of the retinal microvasculature.

Comprehensive glaucoma analysis tools for quantification of optic nerve head, retina nerve fiber layer DDLS ganglion layer and asymmetry.

Anterior examinations – angle to angle complete anterior chamber and pachymetry.

For further information contact: Visionary Surgical Solutions T: +44 (0)1246 252 810 E: admin@visionarysurgicalsolutions.com www.visionarysurgicalsolutions.com www.natural-necessity.com

For further information contact: BIB ophthalmic instruments T: +44 (0)1438 740823 E: sales@bibonline.co.uk www.bibonline.co.uk

• • • • •

86

Helps maintain normal eye function and health.

Helps maintain ocular integrity and structure.

Helps support capillary health in the eye.

Promotes long-term ocular health.

This is based on both clinical experience and research findings over the past eight years.

eye news | AUGUST/SEPTEMBER 2017 | VOL 24 NO 2 | www.eyenews.uk.com

NEWS AND PRODUCT UPDATE

Duckworth & Kent celebrate the opening of their expanded headquarters Duckworth & Kent goes from strength to strength with the announcement that work has now been completed on the expansion of its headquarters in Baldock, Hertfordshire, England.

This extension will enable the company to continue the implementation of new technologies in order to drive innovation and an enduring commitment to exceptional engineering within the field of reusable titanium ophthalmic instrumentation. With increasing surgical challenges and demanding customer expectations, the value of applying innovative design and advanced manufacturing is greater than ever before.

Duckworth & Kent’s Managing Director says ‘Thanks to emerging markets and a continual demand for high quality reusable titanium instruments, Duckworth & Kent has successfully expanded its operations in order to continue being at the leading edge of ophthalmic

instrumentation’.

Duckworth & Kent’s expertise was established over 50 years ago and lies in the use of high quality titanium alloy, a lightweight, non-magnetic, non-corrosive, non-reflective and durable material. These advantageous properties actively benefit the instruments when compared to reusable stainless steel equivalents.

The increased foot print of Duckworth & Kent’s facility will allow it to remain a world leader in reusable titanium ophthalmic instrumentation, manufacturing a comprehensive product range from concept through to the surgeon’s hand.

For further information contact: Duckworth & Kent T: +44 (0)1462 893254 E: info@duckworth-and-kent.co.uk www.duckworth-and-kent.com

IPCL – the Implantable Phakic Contact Lens

Inject comfortably, the 500XLS

The Implantable Phakic Contact Lens is like a soft contact lens, single piece posterior chamber phakic IOL. It can be inserted through a 2.8mm incision and is made of a hybrid acrylic material. The wide product range includes phakic IOLs to correct myopia, hypermetropia, astigmatism and presbyopia. The IPCL is ideal for young patients who require refractive correction or patients who are not suitable for LASIK or LASEK and has the benefit of being reversible. Key features: New spring haptic pad design provide excellent wtw positioning, central optic hole has been specially designed to cause no visual disturbance, smart toric design with no requirement for axis marking, patented unique presbyopic trifocal optic, power range +15D to -30D with cylinder up to 10D and simple loading.

The 500XLS is a high performance ophthalmic examination chair ideally suited for intraocular injection clinics.

This budget chair has multifunctional capability.

Its versatile design supports a wide range of applications.

Please further information contact: Spectrum T: +44 (0)1625 618816 E: info@spectrum-uk.co.uk www.spectrum-uk.co.uk

• • • •

Multifunctional head rest Manual keypad with four memory positions Removable foot operated keypad Four powerful drives for adjusting the backrest, footrest, seat elements and overall chair operating height.

For further information contact: Carleton T: +44 (0)1494 775811 E: carleton@carletonltd.com www.carletonltd.com

Aspire launches Eysano®: first preservative free Timolol eye drops in a multidose device Aspire Pharma recently launched Eysano 2.5mg/ ml and 5mg/ml eye drops, solution (Timolol), a new preservative free eye drop indicated in ocular hypertension, chronic open-angle glaucoma including aphakic patients, and in some adult patients with secondary glaucoma [1].

Eysano is an innovation for the UK market being the first preservative free solution of Timolol in a multidose device.

Eysano is the first in a new range of preservative free ophthalmic medications from Aspire Pharma to be marketed under the ‘ey’ brand.

Aspire’s Managing Director, Graham Fraser-Pye stated: “We are delighted to be launching the first multidose preservative free version of Timolol to the UK market. Eysano is an innovation for

patients and for those healthcare professionals treating glaucoma.“ About Aspire Pharma Aspire Pharma, is a British company established in 2009. The company specialises in the licensing and marketing of both branded and generic medicines with a clear focus on value and sustainability. Aspire aims to develop products that are differentiated and designed to meet the needs of Healthcare professionals and patients.

Reference: 1. Eysano SmPCs For further information contact: Aspire Pharma Ltd E: info@aspirepharma.co.uk www.aspirepharma.co.uk

eye news | AUGUST/SEPTEMBER 2017 | VOL 24 NO 2 | www.eyenews.uk.com

87

NEWS AND PRODUCT UPDATE

Haag-Streit UK appoints a new Customer Services Co-ordinator to strengthen the team Haag-Streit UK (HS-UK) is pleased to announce the appointment of Reece Boughtwood in the role of Customer Services Co-ordinator.

Reece will be responsible for dealing with HS-UK orders, enquiries and quotations, as well as providing customers with technical information on HS-UK products.

Reece has previously held a variety of customer-facing roles which involved liaising with clients over the telephone, dealing with enquiries and completing administrative tasks. He has also recently completed a two-year extended Diploma in Business.

Speaking about his appointment, Reece said, “I am really excited to start my new role at HS-UK. I feel lucky to be part of a fantastic team and I’m looking forward to the challenges that this busy role will bring.”

For further information contact: Haag-Streit UK T: +44 (0)1279 883829 E: info@haag-streit-uk.com www.haagstreituk.com

Extending depth of focus with the IC-8® IOL By applying the simple principles of small aperture to the reliable quality of a monofocal IOL, the IC-8 IOL restores the natural range of vision and provides greater freedom from glasses.

The design includes a non-diffractive 3.23mm diameter opaque mask with a 1.36mm central aperture, which creates a pinhole effect to deliver nearly 3.0 diopters of extended depth of focus.

The unique design of this lens: • • • • •

Delivers good image quality across the entire range of vision.

Provides a continuous range of vision without ‘sweet spots.’

Gives surgeons a premium lens option for patients with an altered cornea (i.e., post-refractive, aberrated corneas, and keratoconus).

Compensates for the effects of astigmatism up to 1.5 diopters.

Continues to be a highly forgiving lens when target refractive endpoints are missed.

For further information contact: Philip Jones T: +44 (0)7777 635257 E: PJones@acufocus.com www.IC8Lens.com

iolAMD eyemax mono – extended macular implant Spectrum are proud to announce that it is now distributing the eyemax mono intraocular lens. eyemax mono is the world’s first microincision injectable implant for treatment of patients with dry AMD and diabetic maculopathy. The eyemax mono is a preloaded single piece lens implanted into the capsular bag during normal cataract surgery through a 2.2/2.5mm incision. The multidimensional hyper-aspheric optic provides high quality images up to 10 degrees of eccentricity from the fovea, capturing the healthier parts of the retina. If required this lens can also produce a modest magnification in combination with glasses after surgery. The optic allows patients to use any part of the macular as though the image had been diverted there by a prism and the technology continues to work even as the disease progresses.

Evidence suggests that patients who have dry AMD when implanted with standard monofocal IOLs during cataract surgery can expect a gain of 6.5-7.5 ETDRS letters compared with 15-24 ETDRS letters gain when implanted with the eyemax mono IOL (eight surgeons in four European study centres).

Ninety-six percent of patients were observed to have an improvement in CDVA & CNVA and the lens has a safety profile similar to that of a standard monofocal implant.

Please further information contact: Spectrum T: +44 (0)1625 618816 E: info@spectrum-uk.co.uk www.spectrum-uk.co.uk

Varilux X series re-invents near vision and creates visual fluidity

Essilor has re-invented near vision at arm’s length and developed the first progressive lens to match the maximum volume of vision that wearers need in the modern world with its revolutionary new Varilux X series design.

It is rolling the new product out along with a new personalisation tools to create the “ultimate vision experience”.

It said that the new lens will change the lives of millions of presbyopes by helping them regain visual agility and spontaneity with very little of the frustrating head movement to “find the sweet spot”.

88

While earlier designs of progressive lenses were based on a single distance for near vision, at 40cm, and in one viewing direction only, this new lens can handle multiple near distances in a 40-70cm arm’s length sphere, giving extended vision.

It will offer a 75% match with wearers’ visual needs within arm’s length, the highest match ever achieved by a progressive lens, compared with the 59% match average from alternative premium progressive designs.

Head of Marketing Jonathan Cohen said: “We will liberate Generation X presbyopes who are

multitasking all day in an accelerated and online world and always feel rushed. Progressive lenses should not slow them down. They expect visual fluidity yet even the latest technology continues to force them to move to find the right vision zone.”

Essilor has also launched a new, exclusive measuring protocol to optimise the new lens at near vision with a new system for opticians to measure a patient’s individual Near Vision Behaviour (NVB). This traps both static posture and dynamic movement of eyes and documents during reading.

Unlike previous varifocal lens personalisation tools which are more oriented to distance vision than near vision, it captures natural posture more accurately, by measuring the wearer seated, reading comfortably, just using an iPad and a brand new clip.

For further information contact: Essilor T: +44 (0)14 54 417100 https://ecp.essilor.co.uk

eye news | AUGUST/SEPTEMBER 2017 | VOL 24 NO 2 | www.eyenews.uk.com

NEWS AND PRODUCT UPDATE

Keeler: helping young ophthalmologists financially for 50 years Since Keeler established its Scholarship Trust in 1967 to mark the company’s 50th anniversary, and its Fellowship Award in 1989 to enable a young ophthalmologist to study a specialised area of ophthalmology for up to a year, 100 people have benefited, with 16 Fellowships awarded. Administered by the Royal College of Ophthalmologists, the Fellowship is awarded every second year.

Professor Philip Bloom, a Trustee of the Keeler Scholarship, was one of its first recipients. It enabled him to fund his Glaucoma Fellowship at Moorfields and the Western Eye Hospital, setting up his career as consultant in a subspeciality.

“The Keeler Scholarship is one of the most prestigious awards in the field of ophthalmology,” commented Prof Bloom. “The fact that it is a substantial amount and has been consistent for so many years demonstrates the breadth and depth of Keeler’s commitment to medical education and to the industry.”

Richard Scawn’s 2012 Fellowship award

supported an oculoplastic and reconstructive fellowship at the University of California San Diego (UCSD) where he gained technical surgical skills and clinical experience under international experts, Dr Kikkawa and Dr Korn. Richard is now passing those skills onto to the next generation of ophthalmologists.

“I’ve always felt a profound responsibility to make the best of the training opportunity the award has afforded me. I’m training as an oculoplastic fellow in Buckinghamshire; I am an instructor at ‘wet lab’ surgical training at the American Academy of Ophthalmology; and an editor of Eyewiki. There is no doubt the award and my fellowship at UCSD were instrumental in helping me achieve these things,” said Richard.

Commenting on the awards, Keeler’s Managing Director Abbas Sotoudeh said: “From Keeler’s perspective, we are absolutely committed to these awards as they play an instrumental role in helping young ophthalmologists get a head

start in their careers, enabling them to go on and perform an important service to society as a whole.”

For further information contact: Keeler Ltd. T: +44 (0)1753 857 177 E: info@keeler.co.uk www.keeler.co.uk

Synthesis – All in One Innovations platform launches successfully in UK Kestrel Ophthalmics, a Cutting Edge company, is delighted to report the successful trial of the NEW Synthesis IOL in a number of NHS hospitals.

Since the launch in April, feedback has been very positive on the delivery system and innovative MICS features of the IOL. The unique homogenous surface across the power range of the 6mm optic produces a consistent injection force, delivering the IOL safely and predictably into the eye.

Injected through as small as a 1.4mm (wound assisted) incision, Synthesis has the enhanced C-Edge+ 360° square edge design (<5μm) for reliable and effective prevention of PCO.

The anatomical diameter design (overall diameters 11mm, 10.7mm and 10.5mm) with 4-point fixation haptics, allows for good centration and positioning in the bag.

For further information contact: Kestrel Ophthalmics T: +44 (0)1202 658444 E: info@kestrelophthalmics.co.uk www.kestrelophthalmics.co.uk

Peer-reviewed review concludes that Second Sight’s Argus® II’s benefit to blind patients justifies its reimbursement Second Sight Medical Products, Inc. the developer, manufacturer and marketer of implantable visual prosthetics that provide some useful vision to blind patients, has welcomed positive conclusions for its Argus® II Retinal Prosthesis System in the most comprehensive literature review published to date in this field.

The paper, published in the journal Eye, examines clinical evidence of benefit and costeffectiveness provided by all current electronic retinal prosthesis devices.

The Argus II captures images on an eyeglassmounted miniature video camera, converts the images to electrical pulses, and then transmits those pulses wirelessly to electrodes implanted on the retinal surface, bypassing defunct retinal cells and stimulating the viable retinal cells in patients with severe to profound retinitis pigmentosa (RP).

The Eye review, of published peer-reviewed literature, is entitled ‘Electronic retinal implants

and artificial vision: journey and present’. It states that, while there are five main retinal devices that are approved or in pre-commercial development stages, the Argus II is one of two devices most likely to succeed in being the first to be used clinically, although only Argus II has published long-term quality of life data results as yet. Fiveyear follow-up data on Argus II was published in Ophthalmology last year (2016), demonstrating long-term safety and clinical benefits. Crucially, the paper demonstrated that increased visual function for implanted patients is maintained long-term.

The Eye review concludes: “The economic argument is clear. Provided device-life is long enough, its cost should be acceptable for the obtained improvement in quality of life.”

NHS England is about to undertake the first publicly funded evaluation trial of the Argus II device in 10 severely blind patients with retinitis pigmentosa, starting later in 2017. For further

information see.

• da Cruz L, Dorn JD, Humayun MS, et al.

Five-Year Safety and Performance Results from the Argus II retinal prosthesis System Clinical Trial.

Ophthalmology 20161;23(10):2248-54.

• Vaidya A, Borgonovi E, Taylor RS, et al. The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients. BMC Ophthalmol 2014;14:49.

For further information contact: Second Sight Medical Products Inc. T: +44 (0)800 520 0925 www.secondsight.com

eye news | AUGUST/SEPTEMBER 2017 | VOL 24 NO 2 | www.eyenews.uk.com

89

NEWS AND PRODUCT UPDATE

PlusoptiX A12c and S12c devices These additions to the established plusoptiX lineup provide lightweight, portable devices that can assist paediatric ophthalmology and optometry departments with accurate, objective results The specifications of the new plusoptiX devices include: • Wireless, faster, accurate, binocular results from 1 metre • Configurable Pass Refer criteria within the screening device • Results provide refraction, symmetry of corneal reflexes, PD and pupil diameter • Data acquisition in under 0.8 second • In built database • Lightweight, portable all encompassing design with touch screen

•

•

Rechargeable battery or mains powered allowing increased flexibility within the clinic or community W-Lan interface for printing and database integration.

For further details and to arrange a demonstration contact: Carleton T: +44 (0)1494 775811 E: carleton@carletonltd.com www.carletonltd.com

Thomson Software Solutions announces the launch of the latest version of the Binocular Vision Analyser in each direction of gaze. Results are plotted in the conventional Hess screen format and may be printed or attached to electronic medical records. The software also includes a variety of analytical tools including the facility to monitor the progression of incomitancies.

The Field of Binocular Single Vision test provides an efficient and accurate replacement for the conventional arc perimeter test. The patient views a stimulus on a large screen display which is scrolled along radial axes, and reports when the stimulus appears doubled. The software automatically plots the resultant fields and charts can be printed or attached to electronic medical records.

Thomson Software Solutions also supplies a range of other software and hardware including the award-winning range of computerised vision Test Charts, the Clinical Eye Tracker, central visual field assessment software and animations for chair-side and waiting room patient education.

Visit our website at for further information.

New Hess screen and Field Binocular Single Vision solution for eye clinics.

The Binocular Vision Analyser is a professional tool for performing accurate Hess Screen and Field of Binocular Single Vision tests. The system was developed in collaboration with orthoptists and is available as software only or as a complete solution including bespoke instrument table, chin

rest, 48” monitor and touch screen PC. The Hess Screen test allows rapid and accurate assessment of the size and direction of phoria / tropia in nine or 25 directions of gaze. The software includes a variety of child-friendly stimuli and also allows torsion to be measured

For further information contact: Thomson Software Solutions T: +44 (0)17 074 14700 E: support: Thomson-software-solutions.com www.thomson-software-solutions.com

News and Product Update is provided as a service to readers and does not imply endorsement by Eye News.

To feature your news here contact Emma O’Sullivan, T: +44 (0)131 557 4184, E: Emma@pinpoint-scotland.com

eyenewsmag Eye News is published by Pinpoint Scotland Ltd, 9 Gayfield Square, Edinburgh, EH1 3NT, UK. T: +44 (0)131 557 4184 F: +44 (0)131 557 4701 www.eyenews.uk.com Pinpoint Scotland Ltd also publish PMFA News, ENT and Audiology News and Urology News.

Publisher Justin Chater

90

eyenewsmagazine

@EyeNewsMag

Editorial Diana Spencer, T: +44 (0)131 557 4184 E: diana@pinpoint-scotland.com

Production Team Charis Stewart Stuart Aitken

Advertising Emma O’Sullivan, T: +44 (0)131 557 4184 E: emma@pinpoint-scotland.com

Subscriptions T: +44 (0)131 557 4184 E: subscriptions@pinpoint-scotland.com

Design & Production Manager Donna Earl, T: +44 (0)131 478 8402 E: donna@pinpoint-scotland.com

Printed by Stephens & George.

Join the Eye News group Copyright: No part of this magazine may be reproduced without written permission from the Publishers. The comments of the contributors are their own and are not necessarily endorsed by the Publisher, Editor or Editorial Board. Accordingly the Publisher, Editor or Editorial Board accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement. The Editor’s decision is final and no correspondence will be entered into. The utmost care has been taken to ensure accuracy of detail, but the Publishers cannot accept responsibility for errors or omissions.

eye news | AUGUST/SEPTEMBER 2017 | VOL 24 NO 2 | www.eyenews.uk.com

NEWS AND PRODUCT UPDATE

Keeler: helping young ophthalmologists financially for 50 years Since Keeler established its Scholarship Trust in 1967 to mark the company’s 50th anniversary, and its Fellowship Award in 1989 to enable a young ophthalmologist to study a specialised area of ophthalmology for up to a year, 100 people have benefited, with 16 Fellowships awarded. Administered by the Royal College of Ophthalmologists, the Fellowship is awarded every second year.

Professor Philip Bloom, a Trustee of the Keeler Scholarship, was one of its first recipients. It enabled him to fund his Glaucoma Fellowship at Moorfields and the Western Eye Hospital, setting up his career as consultant in a subspeciality.

“The Keeler Scholarship is one of the most prestigious awards in the field of ophthalmology,” commented Prof Bloom. “The fact that it is a substantial amount and has been consistent for so many years demonstrates the breadth and depth of Keeler’s commitment to medical education and to the industry.”

Richard Scawn’s 2012 Fellowship award

supported an oculoplastic and reconstructive fellowship at the University of California San Diego (UCSD) where he gained technical surgical skills and clinical experience under international experts, Dr Kikkawa and Dr Korn. Richard is now passing those skills onto to the next generation of ophthalmologists.

“I’ve always felt a profound responsibility to make the best of the training opportunity the award has afforded me. I’m training as an oculoplastic fellow in Buckinghamshire; I am an instructor at ‘wet lab’ surgical training at the American Academy of Ophthalmology; and an editor of Eyewiki. There is no doubt the award and my fellowship at UCSD were instrumental in helping me achieve these things,” said Richard.

Commenting on the awards, Keeler’s Managing Director Abbas Sotoudeh said: “From Keeler’s perspective, we are absolutely committed to these awards as they play an instrumental role in helping young ophthalmologists get a head

start in their careers, enabling them to go on and perform an important service to society as a whole.”

For further information contact: Keeler Ltd. T: +44 (0)1753 857 177 E: info@keeler.co.uk www.keeler.co.uk

Synthesis – All in One Innovations platform launches successfully in UK Kestrel Ophthalmics, a Cutting Edge company, is delighted to report the successful trial of the NEW Synthesis IOL in a number of NHS hospitals.

Since the launch in April, feedback has been very positive on the delivery system and innovative MICS features of the IOL. The unique homogenous surface across the power range of the 6mm optic produces a consistent injection force, delivering the IOL safely and predictably into the eye.

Injected through as small as a 1.4mm (wound assisted) incision, Synthesis has the enhanced C-Edge+ 360° square edge design (<5μm) for reliable and effective prevention of PCO.

The anatomical diameter design (overall diameters 11mm, 10.7mm and 10.5mm) with 4-point fixation haptics, allows for good centration and positioning in the bag.

For further information contact: Kestrel Ophthalmics T: +44 (0)1202 658444 E: info@kestrelophthalmics.co.uk www.kestrelophthalmics.co.uk

Peer-reviewed review concludes that Second Sight’s Argus® II’s benefit to blind patients justifies its reimbursement Second Sight Medical Products, Inc. the developer, manufacturer and marketer of implantable visual prosthetics that provide some useful vision to blind patients, has welcomed positive conclusions for its Argus® II Retinal Prosthesis System in the most comprehensive literature review published to date in this field.

The paper, published in the journal Eye, examines clinical evidence of benefit and costeffectiveness provided by all current electronic retinal prosthesis devices.

The Argus II captures images on an eyeglassmounted miniature video camera, converts the images to electrical pulses, and then transmits those pulses wirelessly to electrodes implanted on the retinal surface, bypassing defunct retinal cells and stimulating the viable retinal cells in patients with severe to profound retinitis pigmentosa (RP).

The Eye review, of published peer-reviewed literature, is entitled ‘Electronic retinal implants

and artificial vision: journey and present’. It states that, while there are five main retinal devices that are approved or in pre-commercial development stages, the Argus II is one of two devices most likely to succeed in being the first to be used clinically, although only Argus II has published long-term quality of life data results as yet. Fiveyear follow-up data on Argus II was published in Ophthalmology last year (2016), demonstrating long-term safety and clinical benefits. Crucially, the paper demonstrated that increased visual function for implanted patients is maintained long-term.

The Eye review concludes: “The economic argument is clear. Provided device-life is long enough, its cost should be acceptable for the obtained improvement in quality of life.”

NHS England is about to undertake the first publicly funded evaluation trial of the Argus II device in 10 severely blind patients with retinitis pigmentosa, starting later in 2017. For further

information see.

• da Cruz L, Dorn JD, Humayun MS, et al.

Five-Year Safety and Performance Results from the Argus II retinal prosthesis System Clinical Trial.

Ophthalmology 20161;23(10):2248-54.

• Vaidya A, Borgonovi E, Taylor RS, et al. The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients. BMC Ophthalmol 2014;14:49.

For further information contact: Second Sight Medical Products Inc. T: +44 (0)800 520 0925 www.secondsight.com

eye news | AUGUST/SEPTEMBER 2017 | VOL 24 NO 2 | www.eyenews.uk.com

89